Oncotarget

Research Papers:

A microRNA biomarker panel for the non-invasive detection of bladder cancer

Virginia Urquidi, Mandy Netherton, Evan Gomes-Giacoia, Daniel J. Serie, Jeanette Eckel-Passow, Charles J. Rosser and Steve Goodison _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:86290-86299. https://doi.org/10.18632/oncotarget.13382

Metrics: PDF 1519 views  |   HTML 2352 views  |   ?  


Abstract

Virginia Urquidi1, Mandy Netherton2, Evan Gomes-Giacoia2, Daniel J. Serie3, Jeanette Eckel-Passow4, Charles J. Rosser1,5, Steve Goodison1,3,6

1Nonagen Bioscience Corporation, Jacksonville, FL, USA

2Cancer Research Institute, MD Anderson Cancer Center, Orlando, FL, USA

3Department of Health Sciences Research, Mayo Clinic, Jacksonville, FL USA

4Department of Health Sciences Research, Mayo Clinic, Rochester, MN USA

5University of Hawaii Cancer Center, Honolulu, HI USA

6Department of Urology, Mayo Clinic, Jacksonville, FL USA

Correspondence to:

Steve Goodison, email: [email protected]

Keywords: diagnostic biomarkers, bladder cancer, microRNA, multiplex, urinalysis

Received: August 15, 2016     Accepted: November 08, 2016     Published: November 16, 2016

ABSTRACT

The development of accurate, non-invasive urinary assays for bladder cancer would greatly facilitate the detection and management of a disease that has a high rate of recurrence and progression. In this study, we employed a discovery and validation strategy to identify microRNA signatures that can perform as a non-invasive bladder cancer diagnostic assay. Expression profiling of 754 human microRNAs (TaqMan low density arrays) was performed on naturally voided urine samples from a cohort of 85 subjects of known bladder disease status (27 with active BCa). A panel of 46 microRNAs significantly associated with bladder cancer were subsequently monitored in an independent cohort of 121 subjects (61 with active BCa) using quantitative real-time PCR (RT-PCR). Multivariable modeling identified a 25-target diagnostic signature that predicted the presence of BCa with an estimated sensitivity of 87% at a specificity of 100% (AUC 0.982). With additional validation, the monitoring of a urinary microRNA biomarker panel could facilitate the non-invasive evaluation of patients under investigation for BCa.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 13382